The Centers for Medicare and Medicaid Services announced that individuals applying for health coverage in the new online marketplace, which is required by the federal health law, will be immediately informed if they qualify for Medicaid or premium subsidies.
The federal government has devoted new funding for Alzheimer's disease research.
An investigational 10% liquid intravenous immunoglobulin product currently under U.S. regulatory review for marketing approval appears to be safe and effective for prophylactic treatment of patients with primary immunodeficiency disorders.
The U.S. Food and Drug Administration approved Baxter International Inc.’s Advate (antihemophilic factor [recombinant] plasma/albumin free method) for hemophilia A.
Factor VIII prophylaxis every other day (qod) or three times weekly is recommended by the National Hemophilia Foundation to prevent joint bleeds in children with severe hemophilia A.
In a move to spark price competition as costs rise, UNICEF is publicizing how much drugmakers are charging it for vaccines.
The 2012 vaccine schedule for children and adolescents incorporates changes for the use of several vaccines adopted over the past year.
In October, the U.S. Department ofHealth and Human Services released a list of critical health priorities for the coming decade designed to serve as a blueprint to help reach the Healthy People 2020 objective of improving the health of all Americans.
The U.S. Department of Health and Human Services is launching two initiatives to help states save money and better coordinate care for the nine million Americans enrolled in both Medicare and Medicaid.
The U.S. departments of Health and Human Services, Labor and the Treasury together published new guidelines requiring health insurers and group health plans to provide consumers with plain language information about their health plans.
Google has invested $3.9 million in PharmaSecure, a mobile application used to verify medication authenticity using text messaging.
Researchers from Kitasato UniversitySchool of Medicine in Japan found that combining intravenous methylprednisolone pulse and intravenous immunoglobulin to treat patients with Kawasaki disease appears safe and effective.